Intesmiran
Productby Moderna
Heard in 7 episodes across 6 shows since Aug 2026
Intesmiran is referenced as Moderna’s individualized mRNA cancer-vaccine candidate, designed to be used with immune-checkpoint therapy for melanoma and potentially other cancers.
Episodes
This week
Expert statements
Share of the conversation
Mentions of Intesmiran per 1,000 mentions of anything, 7-day rolling, across the podcasts PodLume Trends follows.
Show the data
| Day | Share (7-day) | Mentions |
|---|---|---|
| Sep 2 | 0.01‰ | 1 |
| Oct 10 | 0.02‰ | 2 |
| Oct 23 | 0.01‰ | 1 |
| Oct 30 | 0.03‰ | 3 |
| Nov 9 | 0.02‰ | 3 |
| Nov 17 | 0.01‰ | 1 |
Email alert
Email me when Intesmiran comes up on a podcast
One email a week at most, with the new episodes that mention Intesmiran. Free, no account needed, unsubscribe in one click.
What experts have said about Intesmiran
3 statements · 3 positive
Positive RCC data would support intismeran efficacy beyond melanoma
“if it's positive, it's going to contribute to this narrative that intusmerion doesn't just work in melanoma, but also in RCC.”
Open the episode · 121 - Breaking Biotech Week End Wrap Up - Nov 7 , 2026Listen at 23:30
Intismarin trains immune systems to target tumor mutations.
“It's an experimental vaccine that trains the patient's immune system to fight tumors by targeting mutations in cancer cells.”
Open the episode · Moderna’s skin cancer breakthrough, a cheap stock for the Community Portfolio & can you time your investments?Listen at 3:53
High-risk melanoma patients could benefit as early as next year if approved.
“could start benefiting from this as early as next year if regulators approve it”
Open the episode · Moderna’s skin cancer breakthrough, a cheap stock for the Community Portfolio & can you time your investments?Listen at 6:05
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
7 episodes featuring Intesmiran, newest first
- Nov 17, 2026
Biotech bets meet a pivotal FDA succession fightBioCentury This WeekNov 17, 2026 - Nov 9, 2026
Biotech investors weigh obesity, RAS drugs and Moderna catalystsBreaking BiotechNov 9, 2026 - Oct 30, 2026
Cancer vaccine data meets market volatility at ESMOThe Readout LoudOct 30, 2026 - Oct 23, 2026
Ramaswamy tests whether provocation can win Ohio RepublicansThe 7Oct 23, 2026 - Oct 10, 2026
Biotech ETFs frame a week of company-specific movesBreaking BiotechOct 10, 2026 - Sep 2, 2026
Moderna turns tumor mutations into personalized cancer vaccinesThe a16z ShowSep 2, 2026